Top down innovation is dead, and the future looks bright.

FORBES: Top Down Innovation Is Dead

Investors need to think a bit longer-term here and realize that even if the atopic dermatitis route turns out to be a dead end, the future of Nucryst is still looking bright.

FORBES: Nucryst's Nano Silver Lining